Depot medroxyprogesterone and bone density

Depot medroxyprogesterone and bone mineral density.

OBJECTIVE To investigate depot medroxyprogesterone (DMPA)-associated bone loss in a general practice setting. DESIGN Forty-eight patients from a single practice who had used DMPA for contraception for more than 2 years. All patients had a serum oestradiol and if the serum level was <52 pmol/l or >52 pmol/l with menopausal symptoms, bone mineral densitometry (BMD) measurements were made at the...

Depot Medroxyprogesterone Acetate and Bone Density

The 2002 National Survey of Family Growth reported that 5.3% of all US women aged 15 through 44 currently using contraception used DMPA.1 Among contraceptors, 13.9% of those aged 15 to 19 and 10.1% of those aged 20 to 24 currently used DMPA compared with 1.6% of those aged 40 to 44.1 Decreasing rates of adolescent pregnancy between 1995 and 2002 are considered to be due in part to increased use...

Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception.

BACKGROUND Several studies report an association between depot medroxyprogesterone acetate (DMPA) injectable contraception and decreased bone mineral density. Adolescents, who are still gaining bone, may be particularly affected, but there has been little study of the association in adolescent users and none following discontinuation. OBJECTIVE To evaluate bone mineral density changes in adol...

Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception.

The association between users of combined oral contraceptives and depot-medroxyprogesterone acetate (DMPA) for contraception and bone mineral density (BMD) has been controversial because of variations among studies. Like other studies, this cross-sectional study compares BMD in users of combined oral contraceptives and DMPA with that in nonusers. Unlike previous studies, we defined long-term us...

Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss.